Diffusion Pharmaceuticals Reports Favorable Safety Data for Dose-Escalation Run-in of Phase 3 INTACT Study in Glioblastoma Multiforme Patients

July 23, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search